Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
Status:
COMPLETED
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.